Tom Powles and David Olmos
Jun 4, 2025, 04:07
Tom Powles: Unsung Prostate Cancer Hero – David Olmos
Tom Powles, Professor at the University of London and Director of Barts Cancer Centre, shared a post on X:
“Uromigos unsung prostate cancer hero ASC025 – David Olmos – 50% 8 year OS for M1 1st line disease – but subgroups (PSMA+ve and BRCA) still have less good outcomes.
Opportunities for further therapy here with PARPi and LuPSMA (+ve PSMA addition and amplitude studies).”
Tom Powles shared findings from ASC025, citing a 50% 8-year overall survival in first-line metastatic prostate cancer. He noted poorer outcomes in PSMA-positive and BRCA subgroups, pointing to PARP inhibitors and LuPSMA as avenues for further therapeutic development.
More posts featuring Tom Powles.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 14:50
Jun 26, 2025, 14:20
Jun 26, 2025, 13:31